Skip to content
PharmaManufacturingIQ

The lightspeed advantage: Lessons in accelerating sterile injectable production

In this article, Jim Donovan, general manager for Pfizer CentreOne, explores the concept of “lightspeed” development under high-pressure situations, such as pandemics and drug shortages.

By PharmaManufacturing IQ Staff
The lightspeed advantage: Lessons in accelerating sterile injectable production
Published: | 5 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

In this article, Jim Donovan, general manager for Pfizer CentreOne, explores the concept of “lightspeed” development under high-pressure situations, such as pandemics and drug shortages, and how these lessons can be applied to optimise SI development processes to meet rising demand.  

Pfizer CentreOne

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information